Termination of packaging of the bacteriophage lambda chromosome: cosQ is required for nicking the bottom strand of cosN

Journal of Molecular Biology
D Cue, M Feiss

Abstract

Termination of packaging of the lambda chromosome involves completion of translocation of the DNA into the head shell, and conversion of the translocation complex into a cleavage complex. The cleavage reaction introduces staggered nicks into the downstream cosN to generate the right cohesive end of the chromosome. cosQ, a site adjacent to cosN, was found to be required for nicking the bottom strand of cosN; bottom strand nicking was also sequence-specific for bps at the nick site. Nicking of the top strand of cosN (cosNL) was stimulated by cosQ, but fidelity and efficiency of cosNL nicking were largely dictated by other cos subsites (i.e. cosB and I2). Aberrant top-strand cleavage within cosQ was observed in the absence of I2, and nicking at a site 8 nt 5' to the normal cosNL nick site occurred in the absence of cosB. The presence of cosQ was found to be insufficient to arrest DNA translocation in vivo, indicating that cosQ, per se, is not a packaging stop signal. A model is presented in which the role of cosQ is to depolarize the asymmetric arrangement of terminase protomers in the translocation complex so that protomers are configured to match the 2-fold rotational symmetry of cosN.

References

Aug 5, 1978·Journal of Molecular Biology·J O ThomasR Weisberg
Jan 1, 1991·Annual Review of Biochemistry·H Murialdo
Jun 1, 1990·Journal of Bacteriology·A Becker, H Murialdo
Apr 1, 1988·Molecular & General Genetics : MGG·M FeissS Christiansen
Dec 5, 1984·Journal of Molecular Biology·S FrackmanM Feiss
Jun 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·M Feiss, W Widner
Feb 1, 1983·Journal of Bacteriology·N Sternberg, S Austin
Feb 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·M FeissW Widner
Dec 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·B Hohn
Sep 1, 1980·Cell·W C Earnshaw, S R Casjens
Sep 1, 1994·Journal of Virology·W W NewcombJ C Brown
Oct 20, 1993·Journal of Molecular Biology·T Dokland, H Murialdo
Oct 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·D Cue, M Feiss
Jun 1, 1995·Molecular Microbiology·C E CatalanoM Feiss
Jun 1, 1997·The EMBO Journal·G MuskhelishviliA A Travers

❮ Previous
Next ❯

Citations

Aug 9, 2008·Annual Review of Genetics·Venigalla B Rao, Michael Feiss
Mar 10, 2016·Annual Review of Virology·Venigalla B Rao, Michael Feiss
Jun 22, 2000·Journal of Molecular Biology·V RavinR W Hendrix
May 6, 2016·PloS One·Choon Seok OhMichael Feiss
Jul 17, 2008·Molecular Microbiology·Tanfis I AlamVenigalla B Rao
Sep 10, 2015·Biomolecular Concepts·Shuang-Yong Xu
Apr 7, 2004·Molecular Microbiology·Jean Sippy, Michael Feiss

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.